NCT04939467View on ClinicalTrials.gov

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

December 16, 2021

Study Completion Date

April 1, 2022

Conditions
Drug Drug Interaction
Interventions
DRUG

Pirfenidone 267 mg Oral Tablet

Fixed sequence use of active product, TID

DRUG

Nintedanib 150 mg Oral Capsule

Fixed sequence use of active product, BID

DRUG

BLD-0409 750 mg Oral Tablet

Fixed sequence use of active product, QD

Trial Locations (1)

33147

Advanced Pharma, Miami

Sponsors

Lead Sponsor

Blade Therapeutics
All Listed Sponsors
lead

Blade Therapeutics

INDUSTRY

NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers | Biotech Hunter | Biotech Hunter